［1］Zanjani ED, Pixley JS, Slotnick N, MacKintosh FR, Ekhterae D, Clemons G. Erythropoietin does not cross the placenta into the fetus［J］. Pathobiology, 1993, 61(3-4): 2115.
［2］Dame C, Fahnenstich H, Freitag P, Hofmann D, Abdul-Nour T, Bartmann P, et al. Erythropoietin mRNA expression in human fetal and neonatal tissue［J］. Blood, 1998, 92(9): 3218-3225.
［3］Fontenay-Roupie M, Bouscary D, Guesnu M, Picard F, Melle J, Lacombe C, et al. Ineffective erythropoiesis in myelodysplastic syndromes: correlation with Fas expression but not with lack of erythropoietin receptor signal transduction［J］. Br J Haematol, 1999, 106(2): 464-473.
［4］Semenza GL, Agani F, Booth G, Forsythe J, Iyer N, Jiang BH, et al. Structural and functional analysis of hypoxia-inducible factor 1［J］. Kidney Int, 1997, 51(2): 553-555.
［6］Fisher JW. Erythropoietin: physiology and pharmacology update［J］. Exp Biol Med (Maywood), 2003, 228(1): 1-14.
［7］Shannon KM, Naylor GS, Torkildson JC, Clemons GK, Schaffner V, Goldman SL, et al. Circulating erythroid progenitors in the anemia of prematurity［J］. N Engl J Med, 1987, 317(12): 728-733.
［8］Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants［J］. Cochrane Database Syst Rev, 2006, 3: CD004863.
［9］Garcia MG, Hutson AD, Christensen RD. Effect of recombinant erythropoietin on "late" transfusions in the neonatal intensive care unit: a meta-analysis［J］. J Perinatol, 2002, 22(2): 108-111.
［10］Kotto-Kome AC, Garcia MG, Calhoun DA, Christensen RD. Effect of beginning recombinant erythropoietin treatment within the first week of life, among very-low-birth-weight neonates, on "early" and "late" erythrocyte transfusions: a meta-analysis［J］. J Perinatol, 2004, 24(1): 24-29.
［11］Tempera A, Stival E, Piastra M, De Luca D, Ottaviano C, Tramontozzi P, et al. Early erythropoietin influences both transfusion and ventilation need in very low birth weight infants［J］. J Matern Fetal Neonatal Med, 2011, 24(8): 1060-1064.
［12］Alvarez Dominguez E, Pérez Fern-ndez JM, Figueras Aloy J, Carbonell Estrany X. Erythropoietin treatment for late anemia after haemolytic disease of the newborn［J］. An Pediatr(Barc), 2010, 73(6): 334-339.
［13］Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades［J］. Nature, 2001, 412(6847): 641-647.
［14］Wang L, Chopp M, Gregg SR, Zhang RL, Teng H, Jiang A, et al. Neural progenitor cells treated with EPO induce angiogenesis through the production of VEGF［J］. J Cereb blood Flow Metab, 2008, 28(7): 1361-1368.
［15］Sifringer M, Brait D, Weichelt U, Zimmerman G, Endesfelder S, Brehmer F, et al. Erythropoietin attenuates hyperoxia-induced oxidative stress in the developing rat brain［J］. Brain Behav Immun, 2010, 24(5): 792-799.
［16］Yamada M, Burke C, Colditz P, Johnson DW, Gobe GC. Erythropoietin protects against apoptosis and increases expression of non-neuronal cell markers in the hypoxia-injured developing brain［J］. J Pathol, 2011, 224(1): 101-109.
［17］Strunk T, Hartel C, Temming P, Matzke N, Zimmer J, Schultz C. Erythropoietin inhibits cytokine production of neonatal and adult leukocytes［J］. Acta Paediatr, 2008, 97(1): 16-20.
［18］McPherson RJ, Juul SE. Recent trends in erythropoietin-mediated neuroprotection［J］. Int J Dev Neurosci, 2008, 26(1): 103-111.
［19］Brown MS, Eichorst D, Lala-Black B, Gonzalez R. Higher cumulative doses of erythropoietin and developmental outcomes in preterm infants［J］. Pediatrics, 2009, 124(4): e681-e687.
［20］Zhu C, Kang W, Xu F, Cheng X, Zhang Z, Jia L, et al. Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy［J］. Pediatrics, 2009, 124(2): e218-e226.
［21］Bierer R, Receny MC, Hartenberger CH, Ohls RK. Erythropoietin concentrations and neurodevelopmental outcome in preterm infants［J］. Pediatrics, 2006, 118(3): e635-e640.
［22］Neubauer AP, Voss W, Wachtendorf M, Jungmann T. Erythropoietin improves neurodevelopmental outcome of extremely preterm infants［J］. Ann Neurol, 2010, 67(5): 657-666.
［23］Kakavas S, Demestiha T, Vasileiou P, Xanthos T. Erythropoetin as a novel agent with pleiotropic effects against acute lung injury［J］. Eur J Clin Pharmacol, 2011, 67(1): 1-9.
［24］Ozer EA, Kumral A, Ozer E, Yilmaz O, Duman N, Ozkal S, et al. Effects of erythropoietin on hyperoxic lung injury in neonatal rats［J］. 2005, 58(1):38-41.
［27］Berkowitz BA, Roberts R. Evidence for a critical role of panretinal pathophysiology in experimental ROP［J］. Doc Ophthalmol, 2010, 120(1): 13-24.
［28］Patel S, Rowe MJ, Winters SA, Ohls RK. Elevated erythropoietin mRNA and protein concentrations in the developing human eye［J］. Pediatr Res, 2008, 63(4): 394-397.
［29］Sato T, Kusaka S, Shimojo H, Fujikado T. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity［J］. Ophthalmology, 2009, 116(9): 1599-1603.
［30］Figueras-Aloy J, Alvarez-Dominguez E, Morales-Ballus M, Salvia-Roiges MD, Moretones-Sunol G. Early administration of erythropoietin in the extreme premature, a risk factor for retinopathy of prematurity?［J］. An Pediatr (Barc), 2010, 73(6): 327-333.
［31］Aher S, Ohlsson A. Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants［J］. Cochrane Database Syst Rev, 2006, 3: CD004868.
［32］Brown MS, Baron AE, France EK, Hamman RF. Association between higher cumulative doses of recombinant erythropoietin and risk for retinopathy of prematurity［J］. J AAPOS, 2006, 10(2): 143-149.
［33］Suk KK, Dunbar JA, Liu A, Daher NS, Leng CK, Leng JK, et al. Human recombinant erythropoietin and the incidence of retinopathy of prematurity: a multiple regression model［J］. J AAPOS, 2008, 12(3): 233-238.
［34］Chen J, Smith LEH. A double-edged sword: erythropoietin eyed in retinopathy of prematurity［J］. J AAPOS, 2008, 12(3): 221-222.
［36］Sullivan S, Schanler RJ, Kim JH, Patel AL, Trawoger R, Kiechl-Kohlendorfer U, et al. An exclusively human milk-based diet is associated with a lower rate of necrotizing enterocolitis than a diet of human milk and bovine milk-based products［J］. J Pediatr, 2010, 156(4): 562-567.
［37］Shiou SR, Yu Y, Chen S, Ciancio MJ, Petrof EO, Sun J, et al. Erythropoietin protects intestinal epithelial barrier function and lowers the incidence of experimental neonatal necrotizing enterocolitis［J］. J Biol Chem, 2011, 286(14): 12123-12132.
［38］Christensen RD, Rothstein G. Erythropoietin affects the maturation pattern of fetal G-CSF-responsive progenitors［J］. Am J Hematol, 1992, 39(2): 108-112.
［39］Ohls RK, Ehrenkranz RA, Das A, Dusick AM, Yolton K, Romano E, et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron［J］. Pediatrics, 2004, 114(5): 1287-1291.
